Regulatory Feasibility of Over-the-Counter Mifepristone and Misoprostol

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2026.0298  
Dr. Lauren J. Ralph  et al.

Points

Researchers evaluated one hundred sixty-eight individuals across three states to determine if they could accurately self-assess their eligibility for medication abortion using only a prototype over-the-counter drug label.
The study found that eighty-eight percent of participants correctly identified whether they were candidates for the medication when compared to the professional assessments provided by on-site clinical staff members.
Most self-selection errors occurred when participants were uncertain about the seventy-day gestational limit or in cases where the individual was not actually pregnant at the time of the screening.
Ninety-three percent of the participants who felt the medication was appropriate for them expressed a strong interest in purchasing the product over-the-counter to avoid appointment and delivery delays.
The findings suggest that mifepristone and misoprostol likely meet the federal safety criteria for non-prescription status which could significantly broaden access to essential reproductive healthcare services for many patients.

Summary

This study evaluated the feasibility of transitioning mifepristone and misoprostol to over-the-counter (OTC) status by assessing whether individuals could accurately self-screen for medication abortion eligibility. Per FDA requirements for non-prescription approval, the research sought to determine if consumers could rely solely on a prototype Drug Facts Label (DFL) to identify contraindications and gestational age limits without clinician intervention. The investigation was conducted across five clinical sites in three U.S. states, recruiting 168 participants aged 15 and older who were currently seeking reproductive care.

The analysis demonstrated that 88% of participants (147 of 168) correctly determined their clinical eligibility for medication abortion based on the provided labeling. Discordant assessments primarily involved uncertainty regarding the ten-week (70-day) gestational limit or participants who were not actually pregnant. Furthermore, 93% of individuals who identified as eligible expressed a preference for purchasing the medication OTC, citing the clarity of the instructional prototype. While the majority felt confident in an autonomous model, a small subset of participants indicated they would still prioritize a formal clinical consultation prior to administration.

The findings suggest that medication abortion patients can achieve high levels of self-selection accuracy using standardized packaging, potentially meeting the regulatory criteria for broader OTC access. By removing the requirement for in-person dispensing or teleconsultation, this model could alleviate barriers related to appointment availability and mail-order latency. However, researchers noted that larger studies across more diverse demographics are necessary to evaluate the safety risks associated with self-screening errors. The study concludes that providing an autonomous pathway for medication abortion is a viable strategy to enhance reproductive health equity while maintaining established safety standards.

Link to the article: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2847536

References

Ralph, L. J., Baba, C. F., Ehrenreich, K., Morris, N., Biggs, M. A., Blanchard, K., Hernández, E., Kapp, N., Kromenaker, T., Perritt, J., Raymond, E., White, K., & Grossman, D. (2026). Accuracy of self-selection for medication abortion using a prototype drug facts label. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2026.0298